Emergent Biosolutions Inc  

(Public, NYSE:EBS)   Watch this stock  
Find more results for EBS
24.90
+0.03 (0.12%)
Aug 29 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 24.63 - 25.41
52 week 17.16 - 28.48
Open 25.00
Vol / Avg. 0.00/199,272.00
Mkt cap 933.18M
P/E 70.59
Div/yield     -
EPS 0.35
Shares 37.48M
Beta 1.05
Inst. own 77%
Nov 5, 2014
Q3 2014 Emergent BioSolutions Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Aug 20, 2014
Morphosys AG On License Agreement With Emergent To Co-Develop And Commercialize Prostate Cancer Drug Candidate MOR209/ES414 - Webcast
Aug 7, 2014
Q2 2014 Emergent BioSolutions Inc Earnings Call - Webcast
Aug 7, 2014
Q2 2014 Emergent BioSolutions Inc. Earnings Release
Jun 26, 2014
Emergent BioSolutions Inc. at Janney Investor 1x1 Day
Jun 24, 2014
Emergent BioSolutions Inc. at JMP Securities Healthcare Conference - Webcast
Jun 5, 2014
Emergent BioSolutions Inc. at Jefferies Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 4.56% 9.68%
Operating margin 7.13% 13.69%
EBITD margin - 20.64%
Return on average assets 2.43% 5.08%
Return on average equity 4.18% 6.69%
Employees 1,353 -
CDP Score - -

Address

SUITE 400, 2273 RESEARCH BLVD
ROCKVILLE, MD 20850
United States - Map
+1-301-7951800 (Phone)
+1-301-7951899 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. The Company operates in two divisions: BioDefense Division and BioSciences Division. It derived substantially all of its product revenues from sales of BioThrax to the United States government, specifically and the United States Department of Health and Human Services (HHS), as well as the United States Department of Defense (DoD). In August 2013, Emergent Biosolutions Inc closed on its acquisition of Bracco Diagnostics Inc.'s Healthcare Protective Products Division. In February 2014, the Company acquired Cangene Corporation.

Officers and directors

Fuad El-Hibri Executive Chairman of the Board
Age: 56
Bio & Compensation  - Reuters
Daniel J. Abdun-Nabi President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Robert G. Kramer Sr. Chief Financial Officer, Interim Executive Vice President - Corporate Services Division, Principal Financial and Accounting Officer, Treasurer
Age: 56
Bio & Compensation  - Reuters
Anatolio B. Cruz III Executive Vice President, General Counsel, Corporate Secretary
Age: 53
Bio & Compensation  - Reuters
Adam Havey Executive Vice President, President - BioDefense Division
Age: 43
Bio & Compensation  - Reuters
Barry A. Labinger Executive Vice President, President - Biosciences Division
Age: 50
Bio & Compensation  - Reuters
Ronald B. Richard Lead Independent Director
Age: 58
Bio & Compensation  - Reuters
Sue Bailey M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
Zsolt Harsanyi Ph.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
George A. Joulwan Independent Director
Age: 74
Bio & Compensation  - Reuters